<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighty-three patients with various <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> [<z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), essential <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (ET), idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (IMF)] were analyzed for the occurrence of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) during treatment with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> (HU) alone or HU following treatment with busulphan (BU) </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 58 patients (29 PV, 14 ET, 12 IMF, 3 unclassified) had been treated with HU </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-five of these patients had been treated with HU alone whereas 18 patients had received both HU and BU </plain></SENT>
<SENT sid="3" pm="."><plain>The follow-up period was 7.8 years </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-five patients had not been treated with HU </plain></SENT>
<SENT sid="5" pm="."><plain>In this patient group, 4 patients had been treated with BU </plain></SENT>
<SENT sid="6" pm="."><plain>The follow-up period was 10.5 years </plain></SENT>
<SENT sid="7" pm="."><plain>In the HU-treated group (n = 58) 7 patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 5 patients <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Five of the 12 patients had been treated with HU alone, and 4 patients had received both HU and BU </plain></SENT>
<SENT sid="9" pm="."><plain>In the non-HU-treated group (n = 25) 1 patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> developed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="10" pm="."><plain>This patient had only been treated with phlebotomies </plain></SENT>
<SENT sid="11" pm="."><plain>It is concluded that treatment with HU is leukemogenic, with an incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> of approximately 14% when used alone </plain></SENT>
<SENT sid="12" pm="."><plain>The incidence is markedly increased to about 30% when HU is preceded by treatment with BU </plain></SENT>
<SENT sid="13" pm="."><plain>HU is not recommended for use in younger patients, in whom non-leukemogenic agents such as alpha-interferon and anagrelide should be used instead </plain></SENT>
</text></document>